They have no money. This move by them is very curious. They may be looking for a buyout using BIEL’s success. Don’t know so I won’t say anymore. JMHO GLTY
Lots of claims about Sofpulse efficacy gathered by comparing 3 BIEL Clinical Trials with 5 Sofpulse Studies.
The problem is no references are provided so that readers can look at how these efficacy claims were arrived at. A legitimate Comparative Analysis would provide source material in the PR for readers to confirm the claims made.
Instead we get the following statement from Sofpulse,
"For full references regarding claims in this news release, contact Endonovo’s Investor Relations."
Sounds like a scam to get attention by a company that had Sales of $73k in 2021 and a Net loss of $3.1 million.